270 related articles for article (PubMed ID: 30848103)
1. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Bakre MM; Ramkumar C; Attuluri AK; Basavaraj C; Prakash C; Buturovic L; Madhav L; Naidu N; R P; Somashekhar SP; Gupta S; Doval DC; Pegram MD
Cancer Med; 2019 Apr; 8(4):1755-1764. PubMed ID: 30848103
[TBL] [Abstract][Full Text] [Related]
2. Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
Attuluri AK; Serkad CPV; Gunda A; Ramkumar C; Basavaraj C; Buturovic L; Madhav L; Naidu N; Krishnamurthy N; Prathima R; Kanaldekar S; Bakre MM
BMC Cancer; 2019 Mar; 19(1):249. PubMed ID: 30894144
[TBL] [Abstract][Full Text] [Related]
3. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.
Ramkumar C; Buturovic L; Malpani S; Kumar Attuluri A; Basavaraj C; Prakash C; Madhav L; Doval DC; Mehta A; Bakre MM
Biomark Insights; 2018; 13():1177271918789100. PubMed ID: 30083053
[TBL] [Abstract][Full Text] [Related]
4. A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.
Gunda A; Basavaraj C; Serkad V CP; Adinarayan M; Kolli R; Siraganahalli Eshwaraiah M; Saura C; Ruiz F; Gomez P; Peg V; Jimenez J; Sprung S; Fiegl H; Brunner C; Egle D; Bhattacharyya GS; Bakre MM
Breast; 2022 Jun; 63():1-8. PubMed ID: 35245746
[TBL] [Abstract][Full Text] [Related]
5. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.
Zhang X; Gunda A; Kranenbarg EM; Liefers GJ; Savitha BA; Shrivastava P; Serkad CPVK; Kaur T; Eshwaraiah MS; Tollenaar RAEM; van de Velde CJH; Seynaeve CMJ; Bakre M; Kuppen PJK
Breast Cancer Res; 2023 Apr; 25(1):40. PubMed ID: 37060036
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin.
Chandra Doval D; Mehta A; Somashekhar SP; Gunda A; Singh G; Bal A; Khare S; Prakash V Serkad C; Adinarayan M; Krishnamoorthy N; Vijay DG; Anantakrishnan R; Bhattacharyya GS; Bakre MM
Breast; 2021 Oct; 59():1-7. PubMed ID: 34098459
[TBL] [Abstract][Full Text] [Related]
7. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.
Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH
Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080
[TBL] [Abstract][Full Text] [Related]
8. Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.
Serkad CPV; Attuluri AK; Basavaraj C; Adinarayan M; Krishnamoorthy N; Ananthamurthy SB; Mallikarjuna SE; Bakre MM
Int J Clin Exp Pathol; 2021; 14(10):1013-1021. PubMed ID: 34760037
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment.
Eshwaraiah MS; Gunda A; Kanakasetty GB; Bakre MM
Cancer Med; 2023 Jun; 12(12):13342-13351. PubMed ID: 37245224
[TBL] [Abstract][Full Text] [Related]
10. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Sengupta AK; Gunda A; Malpani S; Serkad CPV; Basavaraj C; Bapat A; Bakre MM
Cancer Med; 2020 Nov; 9(21):7810-7818. PubMed ID: 33027559
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
12. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
13. The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution.
Tokunaga E; Ijichi H; Tajiri W; Masuda T; Takizawa K; Ueo H; Koga C; Tanaka J; Nakamura Y; Ohno S; Taguchi K; Okamoto M
Breast Cancer; 2020 Nov; 27(6):1137-1146. PubMed ID: 32472474
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.
Thangarajah F; Enninga I; Malter W; Hamacher S; Markiefka B; Richters L; Krämer S; Mallmann P; Kirn V
Anticancer Res; 2017 Apr; 37(4):1957-1964. PubMed ID: 28373466
[TBL] [Abstract][Full Text] [Related]
15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
16. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Penault-Llorca F; Dalenc F; Chabaud S; Cottu P; Allouache D; Cameron D; Grenier J; Venat Bouvet L; Jegannathen A; Campone M; Debled M; Hardy-Bessard AC; Giacchetti S; Barthelemy P; Kaluzinski L; Mailliez A; Mouret-Reynier MA; Legouffe E; Cayre A; Martinez M; Delbaldo C; Mollon-Grange D; Macaskill EJ; Sephton M; Stefani L; Belgadi B; Winter M; Orfeuvre H; Lacroix-Triki M; Bonnefoi H; Bliss J; Canon JL; Lemonnier J; Andre F; Bachelot T
ESMO Open; 2024 May; 9(5):103443. PubMed ID: 38692082
[TBL] [Abstract][Full Text] [Related]
18. Prognostic study for isolated local recurrence operated with salvage excision in hormone-receptor-positive patients with invasive breast cancer after primary breast surgery.
Yu CC; Kuo WL; Shen SC; Chou HH; Lo YF; Yu MC; Chen SC
Biomed J; 2020 Feb; 43(1):83-93. PubMed ID: 32200960
[TBL] [Abstract][Full Text] [Related]
19. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Tutt A; Wang A; Rowland C; Gillett C; Lau K; Chew K; Dai H; Kwok S; Ryder K; Shu H; Springall R; Cane P; McCallie B; Kam-Morgan L; Anderson S; Buerger H; Gray J; Bennington J; Esserman L; Hastie T; Broder S; Sninsky J; Brandt B; Waldman F
BMC Cancer; 2008 Nov; 8():339. PubMed ID: 19025599
[TBL] [Abstract][Full Text] [Related]
20. Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
Ryu JM; Choi HJ; Kim I; Lee SK; Yu J; Kim JE; Kang BI; Lee JE; Nam SJ; Kim SW
Breast Cancer Res Treat; 2018 Dec; 172(3):627-636. PubMed ID: 30218195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
